These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 23629724)
1. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Hoenigl M; Duettmann W; Raggam RB; Seeber K; Troppan K; Fruhwald S; Prueller F; Wagner J; Valentin T; Zollner-Schwetz I; Wölfler A; Krause R Antimicrob Agents Chemother; 2013 Jul; 57(7):3262-7. PubMed ID: 23629724 [TBL] [Abstract][Full Text] [Related]
2. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685 [TBL] [Abstract][Full Text] [Related]
3. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience. Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709 [TBL] [Abstract][Full Text] [Related]
4. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Bartelink IH; Wolfs T; Jonker M; de Waal M; Egberts TC; Ververs TT; Boelens JJ; Bierings M Antimicrob Agents Chemother; 2013 Jan; 57(1):235-40. PubMed ID: 23114771 [TBL] [Abstract][Full Text] [Related]
5. Adverse reactions to voriconazole. Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850 [TBL] [Abstract][Full Text] [Related]
6. Voriconazole concentrations and outcome of invasive fungal infections. Miyakis S; van Hal SJ; Ray J; Marriott D Clin Microbiol Infect; 2010 Jul; 16(7):927-33. PubMed ID: 19845698 [TBL] [Abstract][Full Text] [Related]
7. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409 [TBL] [Abstract][Full Text] [Related]
8. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251 [TBL] [Abstract][Full Text] [Related]
9. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Choi SH; Lee SY; Hwang JY; Lee SH; Yoo KH; Sung KW; Koo HH; Kim YJ Pediatr Blood Cancer; 2013 Jan; 60(1):82-7. PubMed ID: 22887791 [TBL] [Abstract][Full Text] [Related]
10. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Howard A; Hoffman J; Sheth A Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830 [TBL] [Abstract][Full Text] [Related]
11. Phase II study on voriconazole for treatment of Chinese patients with malignant hematological disorders and invasive aspergillosis. Zhang XZ; Huang XE; Xu YL; Zhang XQ; Su AL; Shen ZS Asian Pac J Cancer Prev; 2012; 13(5):2415-8. PubMed ID: 22901231 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Seyedmousavi S; Mouton JW; Verweij PE; Brüggemann RJ Expert Rev Anti Infect Ther; 2013 Sep; 11(9):931-41. PubMed ID: 24053274 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370 [TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit. Wang Y; Wang T; Xie J; Yang Q; Zheng X; Dong W; Xing J; Wang X; Dong Y Pharmacotherapy; 2016 Jul; 36(7):757-65. PubMed ID: 27284960 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811 [TBL] [Abstract][Full Text] [Related]
17. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. Chu HY; Jain R; Xie H; Pottinger P; Fredricks DN BMC Infect Dis; 2013 Feb; 13():105. PubMed ID: 23442261 [TBL] [Abstract][Full Text] [Related]
18. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313 [TBL] [Abstract][Full Text] [Related]